Kiniksa Pharmaceuticals/$KNSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Ticker
$KNSA
Sector
Primary listing
Employees
-
Headquarters
Website
KNSA Metrics
BasicAdvanced
$2.8B
573.78
$0.07
0.05
-
Price and volume
Market cap
$2.8B
Beta
0.05
52-week high
$39.43
52-week low
$17.82
Average daily volume
422K
Financial strength
Current ratio
3.567
Quick ratio
2.883
Long term debt to equity
1.463
Total debt to equity
1.973
Profitability
EBITDA (TTM)
5.977
Gross margin (TTM)
53.11%
Net profit margin (TTM)
0.90%
Operating margin (TTM)
0.85%
Effective tax rate (TTM)
66.41%
Management effectiveness
Return on assets (TTM)
0.46%
Return on equity (TTM)
1.03%
Valuation
Price to earnings (TTM)
573.778
Price to revenue (TTM)
5.192
Price to book
5.67
Price to tangible book (TTM)
5.85
Price to free cash flow (TTM)
41.335
Free cash flow yield (TTM)
2.42%
Free cash flow per share (TTM)
0.917
Growth
Revenue change (TTM)
56.18%
Earnings per share change (TTM)
-144.69%
3-year revenue growth (CAGR)
80.51%
3-year earnings per share growth (CAGR)
-65.61%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
Bulls say / Bears say
For Q2 2025, ARCALYST generated $156.8 million in net product revenue, representing 52% year-over-year growth and leading to an increased 2025 sales outlook of $625–$640 million, highlighting strong commercial momentum in recurrent pericarditis. (GlobeNewswire)
Kiniksa has started the dose-finding phase of the Phase 2/3 trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, moving forward with a potentially differentiated monthly subcutaneous therapy. (GlobeNewswire)
As of June 30, 2025, Kiniksa had $307.8 million in cash and equivalents and no debt, providing a strong balance sheet to support its Phase 3 programs and ongoing operations. (GlobeNewswire)
The company discontinued development of abiprubart in Sjögren’s disease and ended its license for mavrilimumab, narrowing its pipeline and incurring about $19–$17 million in expected termination-related expenses. (FierceBiotech)
Total operating expenses increased to $136.6 million in Q2 2025, up from $108.7 million a year earlier, mainly due to higher collaboration costs and share-based compensation, which could pressure future profitability. (GlobeNewswire)
KPL-387’s Phase 2/3 results are not expected until the second half of 2026, so potential market entry is unlikely before 2028/2029, leaving the company heavily reliant on ARCALYST for revenue. (SEC Form 10-K; GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
KNSA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $2.8B as of October 11, 2025.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 573.78 as of October 11, 2025.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.05. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.